Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07639164

Stronger Together: Antenatal Depressive Symptoms - Prevalence and Digital Treatment

The main objective of the current research project is to evaluate the usability, satisfaction of the antenatal iCBT program including telephone coaching for antenatal and postnatal depressive symptoms and collect nationally representative data on population-based screening of antenatal depressive and anxiety symptoms. The overarching hypothesis is that iCBT, with easy access and affordability, is user friendly and well accepted. In addition to examining the treatment response by questionnaires, we will study the infant development comprehensively as well as potential physiological changes associated with antenatal depression or its treatment.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Depression / Major Depressive Disorder Antenatal Depression Behavior Behavioral Symptoms Depression Depressive Disorder Depressive Disorder, Major Mental Disorders Mood Disorders

Age range

18 year–55 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

University of Turku

Turku, Finland

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • fluent in written and spoken Finnish or Swedish
  • access to computer or mobile phone with internet
  • between 12 and 22 weeks pregnant
  • screening and baseline score on the EPDS ≥10 points

Exclusion criteria

  • lifetime history of psychotic disorder (e.g. schizophrenia, schizoaffective disorder, bipolar disorder, psychotic depression)
  • active suicidal ideation
  • severe substance abuse or dependence
  • participates in another intervention study aiming at treating the symptoms of antenatal depression

Treatment and study plan

Digitalized CBT with phone coaching

Behavioral

Digitally delivered CBT intervention with weekly phone coaching

Primary outcomes

  1. Change in the Edinburgh Postnatal Depression Scale (EPDS)

    Time frame: Baseline and 11 weeks after baseline

    EPDS is a ten-item self-report questionnaire originally developed to screen for postpartum depression. The respondents are asked about the symptoms of depression. The total score ranges from 0 to 30.

Secondary outcomes

  1. Change in the General Anxiety Disorder 7-item scale (GAD-7)

    Time frame: Baseline and 11 weeks after baseline

    To assess the change in anxiety symptoms from baseline to follow-up, we will use the Generalized Anxiety Disorder 7-item Scale (GAD-7) (Spitzer, Kroenke, Williams, & Löwe, 2006), which is a brief screening measure including seven items asking about anxiety symptoms experienced in the previous two weeks.

  2. Change in the Beck Depression Inventory II (BDI-II)

    Time frame: Baseline and 11 weeks after baseline

    To assess the change in depressive symptoms BDI-II will be used.

  3. Social Phobia Inventory (SPIN)

    Time frame: Baseline and 11 weeks after baseline

    To assess the change in Social Phobia SPIN will be used

  4. Pregnancy-Related Anxiety Questionnaire-Revised (PRAQ)

    Time frame: Baseline and 11 weeks after baseline

    To assess the change in pregnancy related anxiety PRAQ will be used

  5. Perceived Stress Scale (PSS)

    Time frame: Baseline and 11 weeks after baseline

    To assess the change in perceived stress PSS will be used

Sponsors and collaborators

Lead sponsor

University of Turku

Other

Registry information

Important dates

Study start
2026
Primary completion
2030
Study completion
2030
First posted
Jun 10, 2026
Registry last updated
Jun 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.